4 - 10 May 2019
These are links to news stories about multiple sclerosis from the last week that may be of interest to people affected by MS in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts.
Ocrevus approved for PPMS
The first disease modifying drug for people with primary progressive MS in England has been approved by NICE. Ocrevus (ocrelizumab) will be available for prescription for people with early, inflammatory primary progressive MS. Talks are underway about availability in the rest of the UK.
MS Trust link: Good news! NICE approves Ocrevus (ocrelizumab) for primary progressive MS (includes the eligibility criteria for the drug)
Lack of services for people with advanced MS
David Martin of the MS Trust talks about the injustice of the two tier system for people with MS, where people who are eligible for a disease modifying drug are more likely to get a good service than those who aren't. He discussed the Advance MS Champions project that is trying to start to address this problem
MS Trust link: Advanced MS Champions
MS in the Media
27 Nov 2020 - 00:00
- Depression affects multitasking in MS
- Benefits process in Scotland
- Cancer risks and multiple sclerosis
- Gut immune cells and relapses
MS in the Media
20 Nov 2020 - 00:00
- New study for advanced MS
- Campaign for fair benefits during the pandemic
- Stem cells compared to Lemtrada
- DMD use and finances
David Martin appointed Chair of the Neurological Alliance
18 Nov 2020 - 00:00
The MS Trust is delighted to announce that CEO David Martin, has been voted in as Chair of the Neurological Alliance.